Shares in Mylan (NSDQ:MYL) remained steady today after the pharmaceutical company missed expectations on Wall Street with its third quarter results.
The Canonsburg, Penn.-based company posted profits of $88.3 million, or 16¢ per share, on sales of $2.99 billion for the 3 months ended Sept. 30, for bottom-line growth of 172% on sales loss of -2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.